Skip to main content
    W

    West Pharmaceutical Services Inc (WST)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $417.95
    +1.53 (+0.37%)

    Market Cap: $29.01B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    West Pharmaceutical Services Inc (WST) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect West Pharmaceutical Services (WST) to earn $9.46 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.42B. Of 16 analysts, 15 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 16 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.

    RatingAnalystsShare
    Strong Buy318.8%
    Buy1275.0%
    Hold00.0%
    Sell00.0%
    Strong Sell16.3%
    Consensus
    Buy
    Total analysts
    16

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 9.8% and revenue estimates rise 5.8%.

    Fiscal year ending Dec 31, 2026
    $9.46
    EPS consensus, revenue $3.42B
    Fiscal year ending Dec 31, 2027
    $10.39
    EPS consensus, revenue $3.62B
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$9.46$9.40 to $9.6316$3.42B$3.41B to $3.45B15
    Dec 31, 2027$10.39$9.97 to $11.0816$3.62B$3.51B to $3.73B15

    Quarterly Estimates

    The EPS consensus rises from $2.31 for the quarter ending Dec 31, 2026 to $2.35 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.31$2.19 to $2.4413$833.44M$804.58M to $870.45M14
    Mar 31, 2027$2.35$2.31 to $2.406$859.21M$834.90M to $895.93M6

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 28 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026160
    Fiscal year ending Dec 31, 2027120

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 5.6% from $8.96.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$9.46$8.96$8.96$8.96$8.96+5.6%
    Fiscal year ending Dec 31, 2027$10.39$9.98$9.98$9.96$9.96+4.3%
    Quarter ending Mar 31, 2027$2.35$2.28$2.30$2.29$2.29+2.4%

    Frequently Asked Questions About WST

    What is the WST stock forecast?

    Consensus analyst estimates put West Pharmaceutical Services's EPS at $9.46 for the fiscal year ending Dec 31, 2026, on revenue of $3.42B. The consensus rating from 16 analysts is Buy.

    How do analysts rate WST stock?

    Of 16 analysts covering West Pharmaceutical Services, 3 rate it Strong Buy, 12 Buy, 0 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from WST next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $9.46, with estimates from $9.40 to $9.63 from 16 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $10.39, with estimates from $9.97 to $11.08 from 16 analysts.

    What revenue do analysts expect from West Pharmaceutical Services next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.42B, with estimates from $3.41B to $3.45B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.62B, with estimates from $3.51B to $3.73B.

    How many analysts cover WST?

    16 analysts rate West Pharmaceutical Services stock, and 16 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.